GC Biopharma Stock Forecast for 2023 - 2025 - 2030
Updated on 04/26/2024
GC Biopharma Stock Forecast and Price Target
Given the average yearlong price target of ₩144000.00 provided by three prominent analysts over the past few months, there is a potential upside of approximately 29.61% from the last closing price in April, 2024 for GC Biopharma's stock if it is reached. This estimation is based on a high estimate of ₩150000.00 and a low estimate of ₩140000.00. If you are not interested in A006280 stock, you may be interested in its competitors.
29.61% Upside
GC Biopharma Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, GC Biopharma's Price has gone down from ₩75.85k to ₩0.00 – a 100.00% drop. In the next year, analysts expect Fair Value to reach ₩38.81k – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
GC Biopharma Revenue Forecast for 2023 - 2025 - 2030
GC Biopharma's Revenue has increased by 13.78% In the last two years, going from ₩1.50T to ₩1.71T. In the next year, analysts expect Revenue to reach ₩1.77T – an increase of 3.59%. For the next seven years, the forecast is for Revenue to grow by 4.87%.
.jpg)
GC Biopharma Dividend per Share Forecast for 2023 - 2025 - 2030
In the last two years, GC Biopharma's Dividend per Share has grown, increasing from ₩1500.00 to ₩1750.00 – a growth of 16.67%. According to 7 analysts, GC Biopharma's Dividend per Share will fall by 0.00% in the next year, reaching ₩1750.00. Professionals believe that By 2030, GC Biopharma's Dividend per Share will fall to ₩1621.74 – a 7.33% decrease from its current value.
GC Biopharma EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, GC Biopharma's EBITDA has grown from ₩98.98B to ₩145.81B – a 47.31% increase. 7 analysts predict GC Biopharma's EBITDA will decrease by 6.28% in the next year, reaching ₩136.64B. Over the next seven years, the forecast is for EBITDA to grow by 8.58%.
GC Biopharma EBIT Forecast for 2023 - 2025 - 2030
In the last two years, GC Biopharma's EBIT has grown by 60.82%, rising from ₩50.19B to ₩80.71B. For the following year, the 7 analysts predict that GC Biopharma's EBIT will drop by 18.31%, reaching ₩65.93B. Over the next seven years, experts predict that GC Biopharma's EBIT will grow at a rate of 14.25%.
GC Biopharma EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, GC Biopharma's EPS has gone down from ₩7095.00 to ₩0.00 – a 100.00% drop. In the next year, analysts expect EPS to reach ₩3630.43 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
.jpg)